NASDAQ: BIOXBioceres Crop Solutions Corp Stock
$11.97-0.15 (-1.24%)
Updated Apr 22, 2024
BIOX Price
$11.97
Fair Value Price
-$8.35
Market Cap
$752.05M
52 Week Low
$9.76
52 Week High
$14.20
P/E
33.81x
P/B
2.5x
P/S
1.92x
PEG
0.4x
Dividend Yield
N/A
Revenue
$450.32M
Earnings
$21.96M
Gross Margin
42%
Operating Margin
12.39%
Profit Margin
4.9%
Debt to Equity
1.61
Operating Cash Flow
$30M
Beta
0.55
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BIOX Overview
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. The company also offers HB4, a drought tolerant seed technology program. It operates in Argentina, Uruguay, France, South Africa, and internationally. The company was founded in 2001 and is headquartered in Rosario, Argentina. Bioceres Crop Solutions Corp. is a subsidiary of Bioceres LLC.
Zen Score
–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIOX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIOX ($11.97) is overvalued by 243.44% relative to our estimate of its Fair Value price of -$8.35 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BIOX ($11.97) is not significantly undervalued (243.44%) relative to our estimate of its Fair Value price of -$8.35 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BIOX ($11.97) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIOX due diligence checks available for Premium users.
Be the first to know about important BIOX news, forecast changes, insider trades & much more!
BIOX News
Valuation
BIOX fair value
Fair Value of BIOX stock based on Discounted Cash Flow (DCF)
Price
$11.97
Fair Value
-$8.35
Undervalued by
243.44%
BIOX ($11.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIOX ($11.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIOX ($11.97) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIOX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
33.81x
Industry
26.68x
Market
41x
BIOX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BIOX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
BIOX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.5x
Industry
1.37x
BIOX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIOX price to earnings growth (PEG)
For valuing profitable companies with growth potential
BIOX is good value based... subscribe to Premium to read more.
PEG Value Valuation
BIOX's financial health
Profit margin
Revenue
$139.5M
Net Income
$108.4k
Profit Margin
0.1%
BIOX's Earnings (EBIT) of $55.81M... subscribe to Premium to read more.
Interest Coverage Financials
BIOX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$819.5M
Liabilities
$484.3M
Debt to equity
1.61
BIOX's short-term assets ($391.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOX's short-term assets ($391.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIOX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$21.1M
Investing
-$18.4M
Financing
$698.7k
BIOX's operating cash flow ($29.61M)... subscribe to Premium to read more.
Debt Coverage Financials
BIOX vs Agricultural Input Stocks
Bioceres Crop Solutions Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.